: Malignant pleural mesothelioma (MPM) is considered a relatively uncommon disease but its incidence is increasing worldwide. Patients affected by MPM have a very severe prognosis and have been often occupationally and environmentally exposed to asbestos. In recent years, checkpoint inhibitors have dramatically revolutionized the paradigm for...
-
2022 (v1)PublicationUploaded on: April 14, 2023
-
2023 (v1)Publication
Small cell lung cancer (SCLC) has been historically considered a homogeneous disease and thus approached as a single entity when it comes to clinical studies design and new treatments developments. However, increasing knowledge in the genetic and molecular landscape of this disease challenges this concept, opening the possibility that different...
Uploaded on: July 3, 2024 -
2017 (v1)Publication
We aimed to evaluate the relationships between circulating tumor cells (CTCs) or plasma cell–free DNA (cfDNA) on one side and a comprehensive range of18F-FDG PET/CT–derived parameters on the other side in chemotherapy-naive patients with advanced non–small cell lung cancer (NSCLC). Methods: From a group of 79 patients included in a trial...
Uploaded on: April 14, 2023 -
2016 (v1)Publication
Lung cancer is still the leading cause of cancer related death worldwide. Fibroblast growth factor receptor (FGFR) is a tirosine-kinase receptor that is seen to be amplified or mutated in non-small cell lung cancer (NSCLC) and it plays a crucial role in tumour development and maintenance. The authors analyzed the state of the art of FGFR by...
Uploaded on: April 14, 2023 -
2015 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2015 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2018 (v1)Publication
Background: Rare cases of severe myocarditis are reported during treatment with nivolumab. Troponin, a biomarker of cardiac damage, is a key component of the diagnostic workup of many cardiac disorders, including myocarditis. This study investigates the role of troponin to assess cardiac involvement during nivolumab therapy for non-small cell...
Uploaded on: April 14, 2023 -
2022 (v1)Publication
Introduction In recent years, immunotherapy has become a pillar in the treatment of advanced, non-oncogene-addicted non-small cell lung cancer (NSCLC). Programmed death ligand 1 (PD-L1) expression is currently the only factor used to predict response to immunotherapy in clinical practice. Specifically, single-agent pembrolizumab as first-line...
Uploaded on: February 11, 2024 -
2019 (v1)PublicationCorrelation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab
Reliable predictors of benefit from immune checkpoint inhibitors in non-small-cell lung cancer (NSCLC) are still limited. We aimed to evaluate the association between the expression of selected molecules involved in immune response and clinical outcomes in NSCLC patients receiving nivolumab. In our study, the outcomes of 46 NSCLC patients...
Uploaded on: April 14, 2023 -
2024 (v1)Publication
Purpose: Pembrolizumab-based regimens are conditioned by the expression of PD-L1, but durable response rate is limited by innate and acquired resistance mechanisms. Here, we focus on osteopontin (OPN), an upfront biomarker of senescence, which closely associated with natural history of non-small cell lung cancer (NSCLC). Methods: Seventy-nine...
Uploaded on: July 3, 2024 -
2022 (v1)Publication
Simple Summary Immune checkpoint blockade (ICB) with antibodies targeting CTLA-4 (Cytotoxic Lymphocyte Antigen 4) and/or programmed death-1 protein (PD-1)/programmed death ligand-1 (PD-L1) has significantly modified the therapeutic landscape of a broad range of human tumor types, including advanced non-small-cell lung cancer (NSCLC). Despite...
Uploaded on: February 4, 2024 -
2019 (v1)Publication
Women treated for breast cancer (BC) are at risk of developing secondary tumors, such as lung cancer (LC). Since rare germline variants have been linked to multiple cancer development, we hypothesized that BC survivors might be prone to develop LC as a result of harboring rare variants. Sixty patients with LC with previous BC (the study...
Uploaded on: April 14, 2023 -
2023 (v1)Publication
The treatment of non-small cell lung cancer (NSCLC) has changed dramatically with the advent of immune checkpoint inhibitors (ICIs). Despite encouraging results, their efficacy remains limited to a subgroup of patients. Circulating immune checkpoints in soluble (s) form and associated with extracellular vesicles (EVs) represent promising...
Uploaded on: February 14, 2024 -
2023 (v1)Publication
Background: Lung cancer patients diagnosed following emergency admission often present with advanced disease and poor performance status, leading to suboptimal treatment options and outcomes. This study aimed to investigate the clinical and molecular characteristics, treatment initiation, and survival outcomes of these patients. Methods: We...
Uploaded on: January 31, 2024